Rennova Health, Inc. RNVA
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | 154.54% | 234.88% | 304.37% | 262.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 154.54% | 234.88% | 304.37% | 262.01% |
| Cost of Revenue | -- | 39.77% | 42.93% | 27.88% | -22.29% |
| Gross Profit | -- | 419.83% | 18,884.48% | 403.02% | 169.39% |
| SG&A Expenses | -- | 37.40% | 24.86% | -3.99% | -41.35% |
| Depreciation & Amortization | -- | -14.02% | -22.34% | -27.07% | -41.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 36.31% | 30.26% | 7.45% | -33.40% |
| Operating Income | -- | 178.37% | 118.25% | 86.21% | 82.29% |
| Income Before Tax | -- | 189.27% | 102.98% | 41.85% | 61.41% |
| Income Tax Expenses | -- | 362.28% | 74.26% | 74.26% | 194.62% |
| Earnings from Continuing Operations | -- | 154.90% | 94.76% | 37.89% | 59.36% |
| Earnings from Discontinued Operations | -- | -103.94% | -100.15% | -100.17% | -100.09% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 166.64% | -103.04% | -158.75% | -154.71% |
| EBIT | -- | 178.37% | 118.25% | 86.21% | 82.29% |
| EBITDA | -- | 200.29% | 126.95% | 90.18% | 84.53% |
| EPS Basic | -- | 100.00% | 100.00% | 99.51% | 98.73% |
| Normalized Basic EPS | -- | 100.00% | 100.00% | 99.24% | 99.60% |
| EPS Diluted | -- | 100.00% | 100.00% | 99.51% | 98.73% |
| Normalized Diluted EPS | -- | 100.00% | 100.00% | 99.24% | 99.60% |
| Average Basic Shares Outstanding | -- | 5,624.18% | 993,503.56% | 1,817,756.03% | 27,969,564.92% |
| Average Diluted Shares Outstanding | -- | 60,165.98% | 7,846,484.81% | 1,817,756.03% | 27,969,564.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |